KELIX bio to Acquire Pharmaceutical Institute (PHI) in Rabat, Morocco

Amneal Pharmaceuticals Acquires Kashiv BioSciences to Build Global Biosimilars Platform

April 22, 2026

Healthcare Services

Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% of Kashiv BioSciences in a deal with $375 million in cash and $375 million in equity at closing, plus up to $350 million in contingent regulatory milestone payments and potential commercial royalties. The acquisition is expected to close in the second half of 2026 and will create a fully integrated global biosimilars platform combining Kashiv’s development and manufacturing capabilities with Amneal’s commercial scale.

KRTL Biotech (KRTL Holding) Acquires Majority Interest in Sigma Corp (Bolivia)

September 2, 2025

Pharmaceuticals

KRTL Biotech, a wholly owned subsidiary of KRTL Holding Group, Inc., completed a merger-by-exchange to acquire 99% of Industria Químico Farmacéutica Sigma Corp. S.R.L. (SIGMA), a Bolivian pharmaceutical manufacturer. The Wilstermann Family received 490,000,000 KRTL Biotech common shares (49% of KRTL Biotech) and Patricia Wilstermann received a preferred share and a permanent board seat; SIGMA will be consolidated into KRTL Biotech's financials under U.S. GAAP.

AmerisourceBergen Acquires PharmaLex for €1.28 Billion

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation signed a definitive agreement to acquire PharmaLex Holding GmbH for €1.28 billion in cash. The deal is intended to expand AmerisourceBergen’s global biopharma services platform by adding PharmaLex’s tech-enabled, regulatory-focused life sciences expertise.

Dipharma Inc. Merges Kalexsyn, Inc. into Parent to Complete Integration

January 4, 2022

Pharmaceuticals

Dipharma Inc., part of the Dipharma Group, has merged Kalexsyn, Inc. (a Michigan corporation acquired in 2018) into its 100% owner, Dipharma Inc., effective January 1, 2022. The merger completes Kalexsyn's formal integration and strengthens Dipharma's U.S. cGMP and CRO capabilities in Kalamazoo to support services from discovery through commercialization.

Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

October 22, 2020

Pharmaceuticals

Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.

Nicox S.A. Acquires Aciex Therapeutics, Inc.

July 2, 2014

Pharmaceuticals

Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.